A hemi‐spleen injection model of liver metastasis for prostate cancer

Liver metastasis is not uncommon in men with metastatic castration‐resistant prostate cancer (mCRPC), estimated at ~20% to 60% of advanced late‐stage patients. Liver and other visceral metastases are associated with worse overall survival. Recent evidence suggests the frequency of visceral metastases may be increasing for reasons that are unclear but may be related to selective pressures induced by modern therapies, including second‐generation antiandrogen receptor signaling inhibitors such as enzalutamide and abiraterone. Consequently, robust models to study the pathobiology of prostate cancer liver metastases and their response to therapy are urgently needed.

• Publication year

  2020

• Venue

  The Prostate

• Publication date

  2020-08-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pros.24055PMID 32761950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study

  2020cited by this paper
• Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

  2018cited by this paper
• Clinical and molecular features of treatment‐related neuroendocrine prostate cancer

  2018cited by this paper
• Luciferase Expression Allows Bioluminescence Imaging But Imposes Limitations on the Orthotopic Mouse (4T1) Model of Breast Cancer

  2017cited by this paper
• Divergent clonal evolution of castration resistant neuroendocrine prostate cancer

  2016cited by this paper
• Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

  2016cited by this paper
• Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

  2016cited by this paper
• Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients

  2016cited by this paper
• A preclinical murine model of hepatic metastases.

  2014cited by this paper
• Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation

  2014cited by this paper
• The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.

  2014cited by this paper
• Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

  2012cited by this paper
• Identification of the murine firefly luciferase-specific CD8 T-cell epitopes

  2009cited by this paper
• Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.

  2005cited by this paper
• Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

  2004cited by this paper
• VCaP, a cell-based model system of human prostate cancer.

  2001cited by this paper
• Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.

  2000cited by this paper
• Cancer cell lines

  1999cited by this paper
• Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines

  1999cited by this paper
• Establishment of two human prostate cancer cell lines derived from a single bone metastasis.

  1997cited by this paper
• Experimental nude mouse model of human colorectal cancer liver metastases.

  1986cited by this paper
• Establishment and characterization of a human prostatic carcinoma cell line (PC-3).

  1979cited by this paper

• Combined Therapy Targeting MET and Pro-HGF Activation Shows Significant Therapeutic Effect Against Liver Metastasis of CRPC

  2025influential citation
• Nonbone Metastasis in Prostate Cancer: Characteristics, Tumor Microenvironment, Diagnosis and Treatment

  2025cites this paper
• SCORT–Cas13d Nanotherapy Precisely Targets the ‘Undruggable’ Transcription Factor HoxB13 in Metastatic Prostate Cancer In Vivo

  2025cites this paper
• Preclinical Models of Solid Cancers for Testing Cancer Immunotherapies

  2025cites this paper
• Orthotopic and metastatic tumour models in preclinical cancer research

  2024cites this paper
• Therapeutic targeting ERRγ suppresses metastasis via extracellular matrix remodeling in small cell lung cancer

  2024cites this paper
• Expression and diagnostic value of abnormal prothrombin and osteopontin in hepatocellular carcinoma with cirrhosis.

  2024cites this paper
• Recent progress of experimental model in pancreatic neuroendocrine tumors: drawbacks and challenges

  2023cites this paper
• Surgical techniques and tips for a reliable murine model of primary and metastatic pancreatic cancer

  2022cites this paper
• Tumor-Derived Exosomes Modulate Primary Site Tumor Metastasis

  2022cites this paper
• Use of FVB Myc-CaP cells as an immune competent, androgen receptor positive, mouse model of prostate cancer bone metastasis

  2021cites this paper
• A novel mouse model for liver metastasis of prostate cancer reveals dynamic tumour‐immune cell communication

  2021cites this paper
• Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer

  2020cites this paper